OmniAb, Inc.
Karen Padilla has a strong background in research and scientific roles. Karen is currently working as a Senior Scientist at OmniAb, Inc. since November 2022. Previously, they held the position of Senior Scientist, Biology at Icagen from July 2015 to November 2022. Before that, they served as a Senior Scientist, Molecular Biology at Neusentis - Pfizer from November 2011 to July 2015. Prior to that, Karen worked at Icagen as a Scientist from June 2003 to November 2011. Karen also has experience as a Research Analyst at Ribonomics, Inc. from July 2001 to May 2003, and as a Research Analyst, Dept. of Surgery at Duke University Medical Center from August 1999 to July 2001. Karen began their career as a Research Analyst at KaroBio USA from April 1998 to August 1999. Karen also worked as a Research Associate II at BD Technologies from 1992 to 1995, and as Research Technician III, Dermatology at UNC-CH School of Medicine from April 1986 to August 1992.
Karen Padilla attended the University of North Carolina at Chapel Hill from an unknown start year to 1987. Karen obtained a Bachelor of Arts degree in Biology and Psychology. Karen then went on to attend the University of North Carolina at Chapel Hill School of Medicine from 1987 to 1989, where they studied Medical Technology. Karen Padilla's education history also includes an additional certification labeled ASCP, although no further details are provided.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.